Sifting through countless of stocks in the Life Sciences Tools & Services industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in IQVIA Holdings Inc. or Bio-Techne Corporation because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how IQVIA Holdings Inc. and Bio-Techne Corporation compare based on key financial metrics to determine which better meets your investment needs.

About IQVIA Holdings Inc. and Bio-Techne Corporation

IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients’ outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with Kexing Biopharm Co., Ltd. for biosimilar development. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. is based in Durham, North Carolina.

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. Its Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Latest Life Sciences Tools & Services and IQVIA Holdings Inc., Bio-Techne Corporation Stock News

As of September 1, 2026, IQVIA Holdings Inc. had a $42.5 billion market capitalization, compared to the Life Sciences Tools & Services median of $2.9 million. IQVIA Holdings Inc.’s stock is up 16.1% in 2026, up 0.1% in the previous five trading days and up 35.4% in the past year.

Currently, IQVIA Holdings Inc.’s price-earnings ratio is 32.0. IQVIA Holdings Inc.’s trailing 12-month revenue is $17.0 billion with a 8.1% net profit margin. Year-over-year quarterly sales growth most recently was 8.7%. Analysts expect adjusted earnings to reach $12.965 per share for the current fiscal year. IQVIA Holdings Inc. does not currently pay a dividend.

As of September 1, 2026, Bio-Techne Corporation had a $11.3 billion market cap, putting it in the 79th percentile of all stocks. Bio-Techne Corporation’s stock is up 22.9% in 2026, down 0.1% in the previous five trading days and up 32.13% in the past year.

Currently, Bio-Techne Corporation’s price-earnings ratio is 62.2. Bio-Techne Corporation’s trailing 12-month revenue is $1.2 billion with a 15.0% net profit margin. Year-over-year quarterly sales growth most recently was 1.3%. Analysts expect adjusted earnings to reach $2.018 per share for the current fiscal year. Bio-Techne Corporation currently has a 0.4% dividend yield.

How We Compare IQVIA Holdings Inc. and Bio-Techne Corporation Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at IQVIA Holdings Inc. and Bio-Techne Corporation’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

IQVIA Holdings Inc. and Bio-Techne Corporation Stock Value Grades

Company	Ticker	Value
IQVIA Holdings Inc.	IQV	D
Bio-Techne Corporation	TECH	F

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

IQVIA Holdings Inc. has a Value Score of 34, which is Expensive. Bio-Techne Corporation has a Value Score of 8, which is Ultra Expensive.

The Value Stock Winner: No Clear Winner

Neither IQVIA Holdings Inc. or Bio-Techne Corporation has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if IQVIA Holdings Inc. or Bio-Techne Corporation is the better investment when it comes to value.

IQVIA Holdings Inc. and Bio-Techne Corporation’s Momentum Grades

Company	Ticker	Momentum
IQVIA Holdings Inc.	IQV	A
Bio-Techne Corporation	TECH	A

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

IQVIA Holdings Inc. has a Momentum Score of 87, which is Very Strong. Bio-Techne Corporation has a Momentum Score of 85, which is Very Strong.

The Momentum Grade Winner: It’s a Tie!

Looking at the Momentum Grade breakdown above, both IQVIA Holdings Inc. and Bio-Techne Corporation have a grade of A. For those who focus solely on a company’s momentum, further research will need to be conducted into both companies to see if they fit your individual needs as an investor.

IQVIA Holdings Inc. and Bio-Techne Corporation’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
IQVIA Holdings Inc.	IQV	C
Bio-Techne Corporation	TECH	D

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

IQVIA Holdings Inc. has a Earnings Estimate Score of 58, which is Neutral. Bio-Techne Corporation has a Earnings Estimate Score of 28, which is Negative.

The Earnings Estimate Revisions Stock Winner: No Clear Winner

Neither IQVIA Holdings Inc. or Bio-Techne Corporation has an Earnings Estimate Revisions Grade that could be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if IQVIA Holdings Inc. or Bio-Techne Corporation is the better investment when it comes to estimate revisions.

Other IQVIA Holdings Inc. and Bio-Techne Corporation Grades

In addition to Value, Momentum and Estimate Revisions, A+ Investor also provides grades for Growth and Quality.

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether IQVIA Holdings Inc. and Bio-Techne Corporation pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, IQVIA Holdings Inc. or Bio-Techne Corporation Stock?

Overall, IQVIA Holdings Inc. stock has a Value Score of 34, Momentum Score of 87 and Estimate Revisions Score of 58.

Bio-Techne Corporation stock has a Value Score of 8, Momentum Score of 85 and Estimate Revisions Score of 28.

Comparing IQVIA Holdings Inc. and Bio-Techne Corporation’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.